ADAMTS13 and thrombotic thrombocytopenic purpura: Beyond hemophilia, an mRNA‐based nanomedicine solution was also investigated for the treatment of thrombotic thrombocytopenic purpura, which is a potentially fatal disease caused by a deficiency of the ADAMTS13 enzyme.[192] Researchers developed an LNP mRNA platform that could produce a wild‐type version of ADAMTS13 or a variant of the enzyme that is resistant to autoantibody induction.